PHILADELPHIA, PA — Carisma Therapeutics Inc. (Nasdaq: CARM) announced its participation in the upcoming American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024. The event will take place in San Diego, California, from November 15 to 19, 2024.
Carisma will present a poster titled “Engineered Macrophages Expressing Fibrosis-Modifying Transgenes Ameliorate Liver Fibrosis in Preclinical Models.” The presentation is scheduled for November 17, 2024, during the session titled “MASLD/MASH – Therapeutics: New Agents.” The poster’s publication number is 3214, and the session will run from 8:00 am to 5:00 pm.
The research highlights Carisma’s innovative approach using engineered macrophages to address liver fibrosis. This preclinical study aims to demonstrate the potential of these modified cells in treating fibrosis, a condition that leads to severe liver damage over time.
Following the start of the poster session, the presentation will be available online in the “Publications” section of Carisma’s website.
The Liver Meeting attracts a global audience of clinicians, researchers, and scientists. It serves as a platform for exchanging the latest research, discussing new treatments and transplantation developments, and networking with top experts in hepatology. Carisma’s participation underscores its commitment to advancing liver disease treatment and sharing groundbreaking research with the medical community.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.